StonvexLoading…
StonvexStonvexStonvexCore line items from IBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $100.00K | $100.00K | $100.00K | $400.00K |
Operating Income | $-23.76M | $-15.40M | $-5.95M | $-18.60M |
Net Income | $-22.44M | $-8.99M | $-5.72M | $-18.38M |
EPS (Diluted) | $-0.25 | $-0.19 | $-0.11 | $-1.75 |
Total Assets | $85.83M | $64.39M | $64.16M | $23.18M |
Total Liabilities | $8.30M | $7.83M | $8.12M | $8.30M |
Cash & Equivalents | $47.63M | $28.67M | $28.11M | $8.58M |
Free Cash Flow OCF − CapEx | $-17.55M | $-11.45M | $-5.70M | $-15.32M |
Shares Outstanding | 34.54M | 30.05M | 20.25M | 19.35M |